Press Releases April 19, 2026 08:00 PM

Abacus Global Management to Participate in the 2026 Milken Institute Global Conference

Abacus Global Management to Participate in the Prestigious 2026 Milken Institute Global Conference

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
ABX

Abacus Global Management, a NYSE-listed alternative asset management company, announced its participation in the 2026 Milken Institute Global Conference. The company's CEO will discuss key trends impacting private wealth, including aging populations, the great wealth transfer, and AI's role in financial advice. Abacus management will also engage in investor meetings during the event.

Abacus Global Management to Participate in the 2026 Milken Institute Global Conference
ABX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Abacus Global Management will participate in the 2026 Milken Institute Global Conference, marking its debut at this influential event.
  • CEO Jay Jackson will speak on the panel addressing private wealth challenges and opportunities, highlighting AI and alternative investments.
  • The company is emphasizing its data-driven wealth solutions and focus on longevity-based assets, targeting institutional and individual clients.

ORLANDO, Fla., April 20, 2026 (GLOBE NEWSWIRE) -- Abacus Global Management, Inc. ("Abacus" or the "Company") (NYSE: ABX), a leader in the alternative asset management industry, today announced that it will participate in the 2026 Milken Institute Global Conference, taking place May 3–6, 2026 at The Beverly Hilton and Waldorf Astoria Beverly Hills in Beverly Hills, CA. The announcement marks the Company's first appearance at the annual gathering, which convenes thousands of leaders from across finance, business, government, health and philanthropy.

Abacus Chairman and CEO Jay Jackson will speak on the conference's "Private Wealth and the Future of Financial Security" panel. This session will explore the defining forces reshaping private wealth today, from aging populations and pension uncertainty to the great wealth transfer, the growing role of alternative investments, and how AI is transforming the delivery of financial advice.

Members of Abacus management, including Chief Financial Officer and Chief Operating Officer Bill McCauley, Chief Investment Officer Elena Plesco and Managing Director of Investor Relations David Jackson, will also be available for one-on-one and small-group investor meetings throughout the conference.

To request a meeting with Abacus management, please email the Company's Investor Relations team at [email protected].

About Abacus

Abacus Global Management (NYSE: ABX) is a leading financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. With a focus on longevity-based assets and personalized financial planning, Abacus leverages proprietary data analytics and decades of industry expertise to deliver innovative solutions that optimize financial outcomes for individuals and institutions worldwide.

For more information, please visit www.abacusgm.com

Contacts:

Investor Relations

Robert F. Phillips – SVP Investor Relations and Corporate Affairs [email protected] (321) 290-1198

David Jackson – Managing Director of Investor Relations [email protected] (321) 299-0716

Abacus Global Management Public Relations [email protected]


Risks

  • The impact of demographic changes and pension uncertainties on the private wealth management sector may affect Abacus's business growth.
  • Competitive pressures in the alternative asset management industry could influence Abacus's market position and profitability.
  • The evolving regulatory environment and economic conditions can pose uncertainties to Abacus's operations and investor confidence.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026